drugset / Trial / NCT01577732

Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers

NCT01577732 ↗

Phase 3 Completed 321 enrolled GlaxoSmithKline
NaSingle-groupOpen-labelPrevention

Summary

This study aims to evaluate the safety and reactogenicity of a booster dose of Infanrix-IPV+Hib™ when administered to healthy Vietnamese toddlers at 12 to 24 months of age who were vaccinated previously against diphtheria, tetanus, and pertussis diseases within their first six months of lives.

Timeline

Start
2012-12-08
Primary completion
2013-04-09
Completion
2013-04-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Infanrix-IPV+Hib™ Vaccine — Intramuscular